Sort   by:  
 Page size 
UnknownRandomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Not available
S-EPMC4372854 | biostudies-literature
UnknownSafety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Not available
S-EPMC5559878 | biostudies-literature
TranscriptomicsSteroid Receptor Coactivator 1 is an Integrator of Glucose and NAD(+)/NADH Homeostasis
SRC-1 affects the expression of complex I of the mitochondrial electron transport chain, a set of enzymes responsible for the conversion of NADH to NAD(+). NAD(+) and NADH were subsequently identified as metabolites that underlie SRC-1's response to glucose deprivation. Knockdown of SRC-1 in glycoly...
ORGANISM(S): Homo sapiens 
2014-04-16 | E-GEOD-56843 | biostudies-arrayexpress
UnknownAdjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.
Not available
S-EPMC6241678 | biostudies-literature
ProteomicsEstrogen Receptor Mutant Coregulator
Biotinylated 4xERE-containing DNA immobilized on streptavidin beads used to pulldown proteins recruited by unliganded WT ER-alpha versus Y537S, D538G, or ESR1-YAP1 fusion proteins from HeLa S3 human cell nuclear extracts.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-02-08 | MSV000080536 | MassIVE
TranscriptomicsCross-platform comparability of microarray data
To facilitate collaborative research efforts between multi-investigator teams using DNA microarrays, we identified sources of error and data variability between laboratories and across microarray platforms and methods to accommodate this variability. RNA expression data were generated in seven labo...
ORGANISM(S): Mus musculus 
2010-06-10 | E-GEOD-2458 | biostudies-arrayexpress
UnknownPara-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.
Not available
S-EPMC10746705 | biostudies-literature
UnknownPosthospitalization COVID-19 cognitive deficits at 1 year are global and associated with elevated brain injury markers and gray matter volume reduction.
Not available
S-EPMC11750706 | biostudies-literature
UnknownPatients with neurological or psychiatric complications of COVID-19 have worse long-term functional outcomes: COVID-CNS-A multicentre case-control study.
Not available
S-EPMC11772688 | biostudies-literature
UnknownAflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
Not available
S-EPMC9714135 | biostudies-literature
Sort   by:  
 Page size